UTX gene mutation “robs” individuals of natural cancer protection
The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
Scientists discover a long noncoding RNA, termed NXTAR, and a small molecule drug that could be used to treat prostate cancer.
The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
An experimental drug enhanced the benefit of immunotherapy, reducing and in some cases eliminating pancreatic cancer in mice.
Professor Ulrich G Steidl received the National Institute of Cancer's Outstanding Investigator Award to study myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
Researchers used Raman spectroscopy to monitor immunotherapy response in mice, potentially improving cancer treatments in the future.
Watch this exclusive interview with Professor Ann Ager, Cardiff University, to discover how CAR T cells could be targeted against solid tumours.
German, Norwegian and British scientists have identified molecular targets for therapies that could prevent breast cancer recurrence.
Activating the protein channel TRPML1 induced selective melanoma cell death while sparing normal cells, suggesting a potential pathway for new cancer therapies.
Scientists have created a nanofibre-based sheet to control and direct the migration of cells, possibly leading to brain tumour therapies.
Washington University will receive $7.5 million from the NIH to study senescent cells for treatments against age-related diseases.
Scientists have identified potential cancer drugs to treat pulmonary hypertension using experimental and computational approaches.
In a new study, a calorie-restricted diet significantly reduced tumour growth in mouse models, suggesting new possibilities for cancer therapies.
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
Boosting dendritic cells prevented immunotherapy resistance in mouse models, suggesting a new approach to colorectal cancer therapies.